SCHEMBL30108236

SCHEMBL30108236

NC(=O)c1cncc(-c2cccnc2)c1

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MKNK1 Q9BUB5 11/20 0.77
▸ MKNK2 Q9HBH9 11/20 0.77
▸ F7 P08709 1/20 0.65
▸ F3 P13726 1/20 0.65
▸ SARM1 Q6SZW1 1/20 0.65
▸ SIRT2 Q8IXJ6 1/20 0.65
▸ SIRT6 Q8N6T7 1/20 0.65
▸ SIRT1 Q96EB6 1/20 0.65
▸ SIRT3 Q9NTG7 1/20 0.65
▸ SIRT5 Q9NXA8 1/20 0.65
▸ SIRT4 Q9Y6E7 1/20 0.65
▸ CHEK2 O96017 1/20 0.59
▸ KMO O15229 1/20 0.58
▸ ALDH1A1 P00352 1/20 0.52
▸ CYP1A2 P05177 1/20 0.52
▸ CYP3A4 P08684 1/20 0.52
▸ CYP2A6 P11509 1/20 0.52
▸ CYP11B2 P19099 2/20 0.51
▸ CYP11B1 P15538 1/20 0.51
▸ CHEK1 O14757 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13188346 1.00 MKNK1 (0.77) MKNK1MKNK2F7F3SARM1
SCHEMBL608617 0.86 KMO (0.73) MKNK1MKNK2F7F3SARM1
SCHEMBL2488476 0.86 MKNK1 (0.77) MKNK1MKNK2SIRT2SIRT1SIRT3
SCHEMBL6754398 0.85 MKNK1 (0.67) MKNK1MKNK2F7F3SARM1
Hydrochloric Acid SCHEMBL30037096 0.85 KMO (0.71) MKNK1MKNK2F7F3SARM1
SCHEMBL1690466 0.84 KMO (0.75) MKNK1MKNK2KMOALDH1A1CYP1A2
SCHEMBL14621505 0.83 MKNK1 (0.59) MKNK1MKNK2KMOALDH1A1CYP1A2
SCHEMBL10028681 0.83 KMO (0.73) MKNK1MKNK2KMOALDH1A1CYP1A2
SCHEMBL10137211 0.83 KMO (0.58) MKNK1MKNK2F7F3SARM1
SCHEMBL606654 0.82 MKNK1 (1.00) MKNK1MKNK2F7F3SARM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12195446-B2 Heteroaryl compounds and their use as therapeutic drugs DONG-A SOCIO HOLDINGS CO., LTD. (KR) 2025-01-14 — — US claimed
US-20230002353-A1 HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS DONG A SOCIO HOLDINGS CO LTD (KR) 2023-01-05 — — US claimed
WO-2025217420-A1 PYRIDINONE COMPOUNDS, METHODS AND USES THEREOF ZENO MANAGEMENT, INC. (US) 2025-10-16 — — WO disclosed
US-12195446-B2 Heteroaryl compounds and their use as therapeutic drugs DONG-A SOCIO HOLDINGS CO., LTD. (KR) 2025-01-14 — — US disclosed
US-20230002353-A1 HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS DONG A SOCIO HOLDINGS CO LTD (KR) 2023-01-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12195446-B2 Heteroaryl compounds and their use as therapeutic drugs MERTK, ERBB2, SRC MKNK1 151/4885MKNK2 190/4885F7 4842/4885
US-20230002353-A1 HETEROARYL COMPOUNDS AND THEIR USE AS THERAPEUTIC DRUGS MERTK, ERBB2, SRC MKNK1 151/4885MKNK2 190/4885F7 4842/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback